FDA Approved Generic Lanreotide Injection
The regulatory agency cleared a generic version of the hormone drug Somatuline Depot for U.S. patients.
Updated on Sept. 18, 2026 in Healthcare
Live Poll
Do you believe the introduction of generic versions of specialized drugs improves patient access to care?
The FDA granted approval for a generic version of lanreotide, produced by Amneal Pharmaceuticals, to treat patients with acromegaly and neuroendocrine tumors. Amneal Pharmaceuticals has launched the 120-milligram injection immediately following the announcement.
Why it matters
This approval introduces a lower-cost alternative to the brand-name drug Somatuline Depot, which saw nearly one billion dollars in annual sales. The drug serves as a critical treatment for controlling hormone levels and improving patient survival outcomes.
The FDA approved a 120-milligram injection strength for the generic medication. This follows annual sales of $983 million for Somatuline Depot during the 12 months ending in July 2026.
The players
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of human and veterinary drugs.
Amneal Pharmaceuticals
Amneal Pharmaceuticals is a specialty pharmaceutical company that develops, manufactures, and distributes generic and specialty drugs for various medical conditions.
The details
The newly approved medication treats acromegaly, carcinoid syndrome, and gastro-enteropancreatic neuroendocrine tumors. It functions by controlling hormone levels and improving progression-free survival while reducing the necessity for rescue therapy in affected patients.
Timeline
Annual sales for Somatuline Depot reached $983 million in the 12 months ending July 2026.
The FDA approved the generic lanreotide injection on September 18, 2026.
Health Landscape
This approval follows the established framework of the Hatch-Waxman Act, which facilitates the market entry of generic medications. Such regulatory actions are central to balancing original pharmaceutical innovation with the broader healthcare goal of increasing drug accessibility.
Patients prescribed lanreotide may soon have access to a new generic alternative that could reduce the cost of ongoing treatment for neuroendocrine tumors. The availability of this 120-milligram injection provides healthcare providers with another option for managing hormone-sensitive conditions.
The takeaway
Generic approvals play a crucial role in lowering costs for patients who rely on long-term hormonal therapy. Individuals should consult their medical providers to determine if switching to a newly available generic is an appropriate step for their specific treatment plan.
Further reading
Learn more about advancements in hormone management and treatment options on our Diabetes page.
Live Poll
Do you believe the introduction of generic versions of specialized drugs improves patient access to care?
